Friday, July 26, 2013

Investopedia: Celgene Only Getting Started, But The Street's Already Looking Ahead

Celgene (Nasdaq:CELG) has been consistently profitable for a while, which is rare enough in the biotech space. What stands out to me with Celgene, though, is that the company has largely been riding just one drug in recent years (Revlimid) and the contributions of newer compounds should offer some very lucrative revenue growth over the next five to ten years. Although the multi-year bull market in biotech has stripped away most of the value from the sector, Celgene is operationally still a very interesting company to watch.

Please continue here:
http://www.investopedia.com/stock-analysis/072613/celgene-only-getting-started-streets-already-looking-ahead-celg-jnj-onxx-abbv.aspx

No comments: